CG Oncology, Inc.
CGON$3.02B
Mid CapNASDAQBiotechnology🇺🇸North America113 employees
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Jun 15, 2026
13wMarket Overview
Stock performance and key metrics
CGON News
Catalyst Timeline
2 upcoming, 1 past
Drug Pipeline
Cretostimogene Grenadenorepvec
High-Risk Non-Muscle-Invasive Bladder Cancer
CG0070
Non Muscle Invasive Bladder Cancer
Ivaltinostat
Metastatic Pancreatic Adenocarcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cretostimogene Grenadenorepvec | Phase 3 | High-Risk Non-Muscle-Invasive Bladder Cancer | - | - |
CG0070 | Phase 2 | Non Muscle Invasive Bladder Cancer | - | - |
Ivaltinostat | Phase 2 | Metastatic Pancreatic Adenocarcinoma | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply